California Challenges Unproven Abortion Reversal Claims in Landmark Legal Battle

After six weeks of testimony in Alameda County, the judge must now decide whether the hormone treatment pushed by Heartbeat International and RealOptions Obria is protected speech — or false advertising under state consumer protection law.

What the state is arguing

Attorney General Rob Bonta filed the suit in 2023 against Heartbeat International, a national anti-abortion nonprofit, and RealOptions Obria, a chain of Northern California crisis pregnancy centers. State lawyers contend there is no scientifically validated way to undo a medication abortion, and that marketing the treatment to patients in distress amounts to consumer fraud. The state is seeking $20 million in penalties under California's false advertising and unfair competition statutes.

In closing arguments, Deputy Attorney General Erica Connolly accused the groups of exploiting patients in "emotional turmoil." "Those individuals need accurate information, but accurate information is not what the defendants provide," she told the court. "Instead, they tout false hope."

How the protocol works — and where the evidence stands

Medication abortion now accounts for roughly two-thirds of all U.S. abortions, according to Guttmacher Institute data cited in the case. The standard regimen uses two drugs taken 24 to 48 hours apart: mifepristone, which blocks progesterone, the hormone that sustains pregnancy, followed by misoprostol, which causes the uterus to contract and empty, a process clinically similar to a miscarriage. The American College of Obstetricians and Gynecologists, the country's leading maternal health medical group, describes "abortion pill reversal" as unproven.

Heartbeat International runs the Abortion Pill Rescue Network, a hotline routing callers to providers who administer high doses of progesterone after mifepristone but before misoprostol, in an attempt to keep the pregnancy going. The organization claims more than 8,000 pregnancies have continued nationwide through its affiliates and cites a success rate between 64% and 68% — figures its own defense team put into the record rather than numbers produced by independent clinical trials.

What the defense is claiming

Defense attorney Paul Jonna argued that because the services are free, California's false advertising law cannot reach them, and characterized the prosecution as "an ideological campaign disguised as consumer fraud prosecution." Defense witnesses, including women who sought to reverse their abortions, testified that they never felt harmed, deceived, or misled, and Jonna noted that no consumer has ever filed a complaint against either organization.

A federal appeals court reached a similar conclusion in a comparable New York case, ruling that reversal claims did not qualify as commercial speech and therefore fell outside that state's advertising law.

What patients navigating this decision should watch for

For anyone who has taken mifepristone and is reconsidering, the courtroom fight is not the same thing as clinical guidance. The practical questions worth asking any provider offering "reversal" services before agreeing to anything: what evidence they cite for their success rate, what follow-up and monitoring they provide, whether they disclose that ACOG does not recognize the protocol as established care, and whether they will document the visit in a way that protects the patient's privacy and continuity with their usual clinician. The legal verdict may eventually constrain how this treatment can be marketed in California — but for now, the burden of sorting marketing from medicine still falls on the patient.